“Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings” published online in Journal of Controlled Release “This preclinical demonstration of the enhanced and more uniform drug and biomarker distribution by stents with deployable coatings could lead to more rapid and improved healing after stent implantation,” said David Kandzari, M.D., Director […]
“Sex Differences in the Outcomes of Stent Implantation in Mini-Swine Model” published in PLOS ONE “Retrospective analyses of pooled animal data can provide important insights into sex-dependent anatomic and pathophysiologic differences,” said Rami Tzafriri, PhD, Director of Research and Innovation, CBSET. LEXINGTON, Mass., Feb. 12, 2018 – CBSET, a non-for-profit preclinical research institute dedicated to […]
Preclinical data to be presented at annual mid-winter meeting of the Association of Research in Otolaryngology (ARO) LEXINGTON, Mass., Feb. 8, 2018 – CILcare Inc.,the world’s leading CRO specializing in hearing therapies, will present preclinical data at the upcoming “ARO 14th Annual Mid-Winter Meeting” in San Diego validating the effect of NAC natural active ingredient in […]
CAMBRIDGE, Mass., Nov. 6, 2017 – CILcare Inc., a leading clinical research organization specializing in ear disorders, and CBSET Inc., a non-profit translational research institute specializing in the advancement of novel therapies, announced today the initiation of a collaboration with Draper, a not-for-profit technology development company focused on the design, development and deployment of advanced […]
LEXINGTON, Mass., November 1, 2017 — CBSET Inc., a non-profit translational research institute that specializes in the advancement of novel therapies, announced today that Internationally renowned cardiologist, Elazer Edelman, MD, PhD, has received the “TCT Career Achievement Award” at TCT 2017 in Denver, Colorado. TCT Directors, Martin B. Leon, MD, and Gregg W. Stone, MD, […]
“This preclinical demonstration of the hindrance of drug distribution by calcified tissue and improved drug delivery after modification of calcified atherosclerotic plaque could have significant clinical implications.” – Michael R. Jaff*, D.O. President, Newton-Wellesley Hospital; Professor of Medicine, Harvard Medical School LEXINGTON, Mass., September 11, 2017 — CBSET Inc., a not-for-profit preclinical research institute dedicated to […]
September 11, 2017—CBSET announced that its scientists have published data and analyses regarding the barrier effects of calcified plaque on drug delivery and the treatment success of adjunctive lesion preparation therapy in the treatment of peripheral atherosclerosis. CBSET is a not-for-profit preclinical research institute dedicated to translational research, education, and advancement of medical technologies. According […]
– “This partnership brings together CBSETs preclinical surgery, drug delivery, and histopathology expertise with CILcare’s proprietary functional tests for assessing alterations to the auditory system in GLP-compliant state-of-the-art facilities. Our new services will enable companies to accelerate their development of novel therapies for hearing loss and be instrumental in supporting their regulatory submissions.” – Peter […]
Company to launch new service at next week’s “ISSCR 2017 Annual Meeting” “CBSET is the ideal partner in preparing, presenting, and defending GLP studies for regulatory review.”—Michael Naimark, CBSET LEXINGTON, Mass., June 8, 2017 — CBSET Inc., a non-profit GLP translational research institute that specializes in the advancement of novel therapies, announced today that it has […]
CBSET, IlluminOss Medical Data Published in Journal of Orthopaedic Research IlluminOss* System provides minimally invasive approach designed to replace splints, casts, metal fixator plates and rods to stabilize broken bones LEXINGTON, Mass., March 23, 2017 — CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, announced today it […]